1.778.600.0509
Advancing the Paradigm of Patient Care

News

November 27, 2023

Asep Medical Holdings Inc. is Granted Patent Approval for its AI-based Sepsis Diagnostic Technology in the US
November 22, 2023

Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc.
November 20, 2023

Asep Inc. in Final Stage of Approval Process for NASDAQ Listing Registration Statement
August 1, 2023

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology
July 18, 2023

Another Breakthrough — Asep Inc.’s A.I.-Based Sepsis Technology Identifies COVID-19 Severity from a Blood Sample
July 5, 2023

Asep Inc. Completes Submission of Registration Statement for NASDAQ Listing
June 26, 2023

Asep Inc. Receives Grant from NanoMedicines Innovation Network (NMIN), Funded by the Government of Canada The New Grant Will Support Important Pre-clinical Studies
June 20, 2023

Asep Inc. Founder, Chair and CEO, Dr. Robert E. W. Hancock, Ranked 4th Best Microbiologist in the World
June 19, 2023

Asep Inc. Undertakes Final Steps Toward NASDAQ Listing
June 12, 2023

Asep Inc. Signs Definitive Agreement for Joint Venture with Bahrain-based Seaspring W.L.L. for Regulatory Approval and Commercialization of Sepsis Diagnosis Technology in the Kingdom of Bahrain, the Middle East and North Africa
June 5, 2023

Asep Inc. Announces Ground-breaking A.I. Technology for Rapid Identification of Severe Sepsis and Improved Superbug Therapies
May 31, 2023

Asep Inc. Engages Aegis Capital Corporation for Listing on NASDAQ Stock Exchange
March 6, 2023

Asep Inc. Appoints General Wesley Clark (Ret.), David Johnson, J. Bernard Rice, Dr. Islam Mohamed and Thomas O’Shaughnessy to its Advisory Board and Dr. Rob Stenstrom, as Medical Director
January 27, 2023

Asep Inc. Signs Joint Venture Term Sheet with Leading Chinese Medical Diagnostic Company Sansure Biotech Inc. in Preparation for the Commercialization of the SepsetER Sepsis Diagnostic Test in China
January 20, 2023

Asep Medical Holdings Inc. Announces Adoption of Long-term Performance Incentive Plan, Grant of Stock Options
January 18, 2023

Asep Medical Holdings Inc. to Hold Important Investor Information Webinar on January 24, 2023
January 6, 2023

Asep Inc. Signs Letter of Intent for Joint Venture with Bahrain-based Seaspring W.L.L. for Regulatory Approval and Commercialization of Sepsis Diagnosis Technology in the Kingdom of Bahrain, the Middle East and North Africa
December 28, 2022

CLARIFICATION Asep Medical Holdings Inc. Provides Update on its Prior Disclosure Regarding Proprietary Diagnostic & Therapeutic Technologies
December 24, 2022

Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic & Therapeutic Technologies
December 22, 2022

Asep Inc. Completes Non-Brokered Private Placement of a $330,000 Unsecured Convertible Debenture
December 2, 2022

Asep Medical Holdings Inc. Enters into Commercial Agreement to Acquire SafeCoat Medical Inc.
November 24, 2022

Asep Medical Holdings Inc. Announces Grant of Stock Options
November 23, 2022

Asep Medical Holdings Inc. Announces Listing of its Common Shares on the Frankfurt Stock Exchange
November 7, 2022

Asep Inc. is Granted Patent Approval for its Sepsis Diagnostic Technology in 13 European Countries and Australia
October 13, 2022

Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility of Peptide-based Oral Rinse for the Chinese Market
October 5, 2022

Asep Inc. Announces the Appointment of Jacqueline M. Tucker as CFO
October 4, 2022

Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur and Author Appointed to Asep Inc.’s Board of Directors
September 13, 2022

Pandemic Preparedness — Asep Inc. supports World Sepsis Day (September 13th) and announces the development of a test kit to identify severe sepsis, the leading cause of death and morbidity in pandemics
July 19, 2022

Asep Medical Inc. Announces Appointment of Dr. Robert E. W. Hancock as CEO and Chairman
June 7, 2022

Asep Medical Holdings Inc. Receives Revocation of Cease Trade Order from the BC Securities Commission.
May 16, 2022

Asep Medical Holdings Inc. Taking Actions for Revocation of Cease Trade Order
April 26, 2022

Asep Medical Holdings Inc. Announces Additional Listing to the OTCQB Venture Market in the U.S.
March 22, 2022

Asep Medical Holdings Inc. Announces Compelling Results of an Independent Sepsis Study Prepared by RTI Health Solutions
March 3, 2022

Asep Medical Holdings Inc. to Hold Online Investor Information Webinar on March 3, 2022
February 19, 2022

Asep Medical Inc. Announces its Antibiofilm/Anti-inflammatory Peptide Technology is in Advanced Development for Wound Dressings with US Army Funding1
February 2, 2022

Asep Medical Holdings Inc. Announces an Exclusive Licensing Arrangement for a Patented and Novel AI-Driven Sepsis Diagnosis Technology Developed at the University of British Columbia (UBC)
January 25, 2022

ASEP Medical Holdings Inc. Announces Additions to its Advisory Board, IR Team, and Digital Marketing Programs
December 16, 2021

ASEP Medical Holdings Inc. Announces Public Listing on Case to Drive Fight Against Antibiotic Failure

ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved